Search

Your search keyword '"Panebianco V"' showing total 593 results
Start Over Author "Panebianco V"
593 results on '"Panebianco V"'

102. PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations

Author

Panebianco, V., Sciarra, A., Berardinis, E., Busetto, G. M., Lisi, D., Buonocore, V., Vincenzo Gentile, Di Silverio, F., and Passariello, R.

Subjects
Adult, Male, Prostatectomy, Magnetic Resonance Spectroscopy, Reverse Transcriptase Polymerase Chain Reaction, Biopsy, Needle, Prostate, Contrast Media, Prostatic Neoplasms, Adenocarcinoma, Middle Aged, Prostate-Specific Antigen, Prognosis, Magnetic Resonance Imaging, Sensitivity and Specificity, Survival Rate, ROC Curve, Antigens, Neoplasm, Humans, RNA, Messenger, dcemr, mrsi, pca3 urinary test, prostate cancer, Ultrasound, High-Intensity Focused, Transrectal, Digital Rectal Examination, Follow-Up Studies, Ultrasonography
Abstract

To compare the prostate antigen 3 (PCA3) test with (1)H-magnetic resonance spectroscopic imaging ((1)H-MRSI) and dynamic contrast-enhanced magnetic resonance imaging (DCEMR) combined examination in the detection of prostate tumor foci in patients with persistently elevated prostate-specific antigen (PSA) levels and prior negative random transrectal ultrasound (TRUS)-guided biopsy.Forty-three patients with a first random biopsy negative for prostate adenocarcinoma, persistent elevated PSA and negative digital rectal examination were recruited. All the patients were submitted to MRSI examination (MRSI-DCEMR) and were submitted to an attentive prostate massage in order to perform PCA3 assay. Afterwards, 10-core laterally-directed random TRUS-guided prostate biopsy was performed.The overall sensitivity and specificity of a PCA3 score ≥35 for positive biopsy were 76.9% and 66.6%, respectively, with a positive predictive value (PPV) of 80% and a negative predictive value (NPV) of 62.5%; as for MRSI sensitivity and specificity were, respectively, 92.8% and 86.6% with a PPV of 92.8% and a NPV of 86.6%. Receiver operating characteristic (ROC) analysis rates were 0.755 for PCA3 and 0.864 for MRSI.Combined MRSI/DCEMR can better improve the cancer detection rate in patients with prior negative TRUS-guided biopsy and altered PSA serum levels than PCA3. Optimization of MRSI will allow more precise diagnosis of local invasion and improved bioptical procedures.

Published
2011

103. Use of the Word “Cured” for Cancer Patients—Implications for Patients and Physicians: The Siracusa Charter

Author

Tralongo, P., primary, Maso, L. Dal, additional, Surbone, A., additional, Santoro, A., additional, Tirelli, U., additional, Sacchini, V., additional, Pinto, C., additional, Crispino, S., additional, Ferraù, F., additional, Mandoliti, G., additional, Tonini, G., additional, Russo, A., additional, Santini, D., additional, Madeddu, A., additional, Panebianco, V., additional, Pergolizzi, S., additional, Respini, D., additional, Rolfo, C., additional, Bongiovanni, M., additional, De Lorenzo, F., additional, Spatola, C., additional, Di Raimondo, F., additional, Terenziani, M., additional, Peeters, M., additional, and Castoro, C., additional

Published
2015
Full Text
View/download PDF

112. Vie biliari

Author

Laghi, Andrea, Panebianco, V., Celestre, M., and Passariello, Roberto

Published
2006

113. Radiologia e diagnostica per immagini

Author

Passariello, Roberto, Bozzao, Alessandro, Fraioli, F, Carbone, Iacopo, Pediconi, Federica, Mastantuono, M, Laghi, Andrea, Napoli, A, Drudi, Fm, Panebianco, V, Bezzi, Mario, and Catalano, Carlo

Published
2006

117. Pancreas endocrino

Author

Panebianco, V, Catalano, Carlo, Laghi, Andrea, Visconti, S, Tancredi, D, Iafrate, F, Danti, M, and Passariello, R.

Published
2003

121. Abdominal MRA

Author

Pavone, P, Laghi, Andrea, Catalano, Carlo, Panebianco, V, Fraioli, F, Baeli, I, and Passariello, R.

Published
2000

124. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer

Author

Sciarra, A., Barentsz, J.O., Bjartell, A., Eastham, J., Hricak, H., Panebianco, V., Witjes, J.A., Sciarra, A., Barentsz, J.O., Bjartell, A., Eastham, J., Hricak, H., Panebianco, V., and Witjes, J.A.

Abstract

Contains fulltext : 97614.pdf (publisher's version ) (Closed access), CONTEXT: Although magnetic resonance imaging (MRI) is emerging as the most commonly used imaging modality for prostate cancer (PCa) detection, treatment planning, and follow-up, its acceptance has not been uniform. Recently, great interest has been shown in multiparametric MRI, which combines anatomic T2-weighted (T2W) imaging with MR spectroscopic imaging (MRSI), dynamic contrast-enhanced MRI (DCE-MRI), and diffusion-weighted imaging (DWI). OBJECTIVE: The aim of this article is to review the current roles of these MR techniques in different aspects of PCa management: initial diagnosis, biopsy strategies, planning of radical prostatectomy (RP) and external radiation therapy (RT), and implementation of alternative focal therapies. EVIDENCE ACQUISITION: The authors searched the Medline and Cochrane Library databases (primary fields: prostatic neoplasm, magnetic resonance). The search was performed without language restriction from January 2008 to November 2010. EVIDENCE SYNTHESIS: Initial diagnosis: The data suggest that the combination of T2W MRI and DWI or MRSI with DCE-MRI has the potential to guide biopsy to the most aggressive cancer foci in patients with previously negative biopsies, increasing the accuracy of the procedure. Transrectal MR-guided prostate biopsy can improve PCa detection, but its availability is still limited and the examination time is rather long. Planning of RP: It appears that adding MRSI, DWI, and/or DCE-MRI to T2W MRI can facilitate better preoperative characterization of cancer with regard to location, size, and relationship to prostatic and extraprostatic structures, and it may also facilitate early detection of local recurrence. Thus, use of these MR techniques may improve surgical, oncologic, and functional management. Planning of external RT and focal therapies: MR techniques have similar potential in these areas, but the published data remain very limited. CONCLUSIONS: MRI technology is continuously evolving, and more extensive use o

Published
2011

125. [MR imaging of pancreatic neoplasms]

Author

Pavone, P., Laghi, Andrea, Catalano, Carlo, Panebianco, V., Pediconi, Federica, Fabiano, S., and Passariello, Roberto

Subjects
Diagnosis, Differential, Pancreatic Neoplasms, Diagnosis: Differential, Predictive Value of Tests, Humans, Magnetic Resonance Angiography, Adenocarcinoma, Magnetic Resonance Imaging
Abstract

The role of MR imaging in the assessment of pancreatic adenocarcinoma is in identification, characterization and staging of the neoplastic lesion. Technique optimization is required in order to obtain high qualities images competitive with spiral CT. The choice of imaging protocol is strictly related to the available equipment as well as fast imaging capabilities. Contrast-enhanced study using breath-hold sequences is required if working at high field strength with high gradient performance; on mid-low field strength nonbreath-hold acquisition techniques, using respiratory compensation techniques, can be implemented. The use of fat saturation pulses may increase the sensitivity of MR in detecting pancreatic lesions. Other advantages of MR imaging are represented by the availability of additional noninvasive techniques for the evaluation of the biliary tree (MR-cholangiopancreatography) and splanchnic vessels (MR-angiography). Lesion identification is based on TIw sequences where the lesion appears hypointense compared with the surrounding pancreas; increased lesion-pancreas contrast is obtained when fat suppression is used. On dynamic studies following gadolinium injection, pancreatic tumors are hypovascular compared with surrounding normal pancreatic gland. Problems in correctly defining the size of the lesions may be encountered in patients presenting with inflammatory changes of the pancreatic parenchyma surrounding the carcinoma (epineoplastic pancreatitis). For lesion characterization MRI is not able to characterize focal pancreatic lesions, allowing a differential diagnosis between pancreatic cancer and focal hypertrophic chronic pancreatitis. Even the use of MR-cholangiopancreatography is not helpful for characterizing focal pancreatic masses. MR imaging is accurate in local staging (assessment of peripancreatic fat infiltration) thanks to the higher contrast resolution, but in vascular staging and in the evaluation of lymphnodal involvement it suffers the same limitations as computed tomography. Future perspective are represented by the use of magnetic resonance angiography for the evaluation of vascular encasement and the use of specific contrast agents for lymphadenopathy. Identification of hepatic metastases with MRI has been proven to be high, with sensitivity and specificity comparable to CT. The use of liver-specific contrast agents (either positive or negative) is becoming almost routine and it is proving to further improve the diagnostic value of MRI.

Published
1999

127. Pancreas

Author

Pavone, P, Catalano, Carlo, Panebianco, V, Laghi, Andrea, Lobina, L, Fanelli, F, and Passariello, R.

Published
1998

129. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma

Author

Cioce, M, primary, Ganci, F, additional, Canu, V, additional, Sacconi, A, additional, Mori, F, additional, Canino, C, additional, Korita, E, additional, Casini, B, additional, Alessandrini, G, additional, Cambria, A, additional, Carosi, M A, additional, Blandino, R, additional, Panebianco, V, additional, Facciolo, F, additional, Visca, P, additional, Volinia, S, additional, Muti, P, additional, Strano, S, additional, Croce, C M, additional, Pass, H I, additional, and Blandino, G, additional

Published
2013
Full Text
View/download PDF

132. Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment.

Author

BARCHETTI, F., STAGNITTI, A., MEGNA, V., ANSARI, N. AL, MARINI, A., MUSIO, D., MONTI, M. L., BARCHETTI, G., TOMBOLINI, V., CATALANO, C., and PANEBIANCO, V.

Abstract

OBJECTIVE: The aim of this study was to evaluate the accuracy of unenhanced whole-body MRI, including whole-body Diffusion Weighted Imaging (DWI), used as a diagnostic modality to detect pathologic lymph nodes and skeletal metastases in patients with prostate cancer (PCa) undergoing restaging after primary treatment. PATIENTS AND METHODS: 152 male patients with biochemical recurrence after radical prostatectomy (RP) or external beam radiation therapy (EBRT) underwent MRI at a 1.5 Tesla magnet with whole spinal sagittal T2-weighted, sagittal T1- weighted, sagittal STIR images, axial T1 and T2- weighted and STIR images of the pelvis and whole-body. 18Fcholine-PET/CT exam was used as the reference standard. RESULTS: MRI protocol including whole-body combined T1-weighted+T2-weighted+STIR+DWI showed a sensitivity (Se) of 99%, a specificity (Spe) of 98%, a positive predictive value (PPV) of 98%, a negative predictive value (NPV) of 96%, an accuracy of 98% and an area under the receiver operating characteristic curve (AUC) of 0.971 for identification of bone metastatic lesion. The same protocol, displayed a Se of 98%, a Spe of 99%, a PPV of 97%, a NPV of 98%, an accuracy of 98 % and an AUC of 0.960 in the detection of pathologic lymph nodes. CONCLUSIONS: Unenhanced whole-body MRI, including whole-body-DWI, is an accurate and cost-effective diagnostic tool which is able to detect lymph node involvement and bone metastases in patients with biochemically recurrent PCa after RP or EBRT. Thanks to its lack of ionizing radiation, excellent soft tissue contrast, high spatial resolution, no need of contrast agent, high Se and Spe, it could play a role in the restaging procedure of such patients. [ABSTRACT FROM AUTHOR]

Published
2016

138. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer

Author

Sacconi, A, primary, Biagioni, F, additional, Canu, V, additional, Mori, F, additional, Di Benedetto, A, additional, Lorenzon, L, additional, Ercolani, C, additional, Di Agostino, S, additional, Cambria, A M, additional, Germoni, S, additional, Grasso, G, additional, Blandino, R, additional, Panebianco, V, additional, Ziparo, V, additional, Federici, O, additional, Muti, P, additional, Strano, S, additional, Carboni, F, additional, Mottolese, M, additional, Diodoro, M, additional, Pescarmona, E, additional, Garofalo, A, additional, and Blandino, G, additional

Published
2012
Full Text
View/download PDF

139. miRNA profiling of gastric tumors unveils tumor suppressor pathway

Author

Biagioni, F., primary, Sacconi, A., additional, Canu, V., additional, Mori, F., additional, Di Benedetto, A., additional, Lorenzon, L., additional, Di Agostino, S., additional, Cambria, A.M., additional, Germoni, S., additional, Grasso, G., additional, Blandino, R., additional, Panebianco, V., additional, Ziparo, V., additional, Federici, O., additional, Muti, P., additional, Strano, S., additional, Carboni, F., additional, Mottolese, M., additional, Diodoro, M.G., additional, Pescarmona, E., additional, Garofalo, A., additional, and Blandino, G., additional

Published
2012
Full Text
View/download PDF

140. Technology & tools development

Author

Pefani, E., primary, Panoskaltsis, N., additional, Mantalaris, A., additional, Georgiadis, M. C., additional, Pistikopoulos, E. N., additional, Aguilar-Mahecha, A., additional, Lafleur, J., additional, Seguin, C., additional, Rosenbloom, M., additional, Przybytkowski, E., additional, Pelmus, M., additional, Diaz, Z., additional, Batist, G., additional, Basik, M., additional, Tavernier, J., additional, Brunet, L., additional, Bazot, J., additional, Chemelle, M., additional, Dalban, C., additional, Guiu, S., additional, di Martino, C., additional, Lehtio, J., additional, Branca, M., additional, Johansson, H., additional, Orre, M., additional, Granholm, V., additional, Forshed, J., additional, Perez-Bercoff, M., additional, Kall, L., additional, Nielsen, K. V., additional, Andresen, L., additional, Muller, S., additional, Matthiesen, S., additional, Schonau, A., additional, Oktriani, R., additional, Wahyono, A., additional, Haryono, S., additional, Utomo, A., additional, Aryandono, T., additional, Gagnon-Kugler, T., additional, Rousseau, C., additional, Alcindor, T., additional, Aloyz, R., additional, Assouline, S., additional, Bachvarov, D., additional, Belanger, L., additional, Camlioglu, E., additional, Cartillone, M., additional, Chabot, B., additional, Christodoulopoulos, R., additional, Courtemanche, C., additional, Constantin, A., additional, Benlimame, N., additional, Dao, I., additional, Dalfen, R., additional, Gosselin, L., additional, Habbab, F., additional, Hains, M., additional, Haliotis, T., additional, Nielsen, T. H., additional, Joncas, M., additional, Kavan, P., additional, Klink, R., additional, Langlaben, A., additional, Lebel, M., additional, Lesperance, B., additional, Mann, K., additional, Masson, J., additional, Metrakos, P., additional, McNamara, S., additional, Miller, W. H., additional, Orain, M., additional, Panasci, L., additional, Paquet, E., additional, Phillie, M., additional, Qureshi, S., additional, Rodrigue, D., additional, Salman, A., additional, Spatz, A., additional, Tetu, B., additional, Tosikyan, A., additional, Tsatoumas, M., additional, Vuong, T., additional, Ruijtenbeek, R., additional, Houtman, R., additional, de Wijn, R., additional, Boender, P., additional, Hilhorst, R., additional, Cohen, Y., additional, Onn, A., additional, Lax, A., additional, Yosepovich, A., additional, Litz, S., additional, Kalish, S., additional, Felemovicius, R., additional, Hout-Silony, G., additional, Gutman, M., additional, Shabtai, M., additional, Rosin, D., additional, Valeanu, A., additional, Winkler, E., additional, Sklair-Levy, M., additional, Kaufman, B., additional, Barshack, I., additional, Canu, V., additional, Sacconi, A., additional, Biagioni, F., additional, Mori, F., additional, di Benedetto, A., additional, Lorenzon, L., additional, di Agostino, S., additional, Cambria, A., additional, Germoni, S., additional, Grasso, G., additional, Blandino, R., additional, Panebianco, V., additional, Ziparo, V., additional, Federici, O., additional, Muti, P., additional, Strano, S., additional, Carboni, F., additional, Mottolese, M., additional, Diodoro, M. G., additional, Pescarmona, E., additional, Garofalo, A., additional, Blandino, G., additional, Ho, T., additional, Feng, L., additional, Lintula, S., additional, Orpana, K. A., additional, Stenman, J., additional, El Messaoudi, S., additional, Mouliere, F., additional, del Rio, M., additional, Guedj, A. S., additional, Gongora, C., additional, Molina, F. M., additional, Lamy, P. J., additional, Lopez-Crapez, E., additional, Rolet, F., additional, Mathonnet, M., additional, Ychou, M., additional, Pezet, D., additional, Thierry, A. R., additional, Manuarii, M., additional, Tredan, O., additional, Bachelot, T., additional, Clapisson, G., additional, Courtier, A., additional, Parmentier, G., additional, Rabeony, T., additional, Grives, A., additional, Perez, S., additional, Mouret, J. F., additional, Perol, D., additional, Chabaud, S., additional, Ray-Coquard, I., additional, Labidi-Galy, I., additional, Heudel, P., additional, Pierga, J. Y., additional, Caux, C., additional, Blay, J. Y., additional, Pasqual, N., additional, and Menetrier-Caux, C., additional

Published
2012
Full Text
View/download PDF

141. P3.10 Microrna Profiling in Gastric Cancer

Author

Canu, V., primary, Sacconi, A., additional, Biagioni, F., additional, Mori, F., additional, di Benedetto, A., additional, Lorenzon, L., additional, di Agostino, S., additional, Cambria, A., additional, Germoni, S., additional, Grasso, G., additional, Blandino, R., additional, Panebianco, V., additional, Ziparo, V., additional, Federici, O., additional, Muti, P., additional, Strano, S., additional, Carboni, F., additional, Mottolese, M., additional, Diodoro, M.G., additional, Pescarmona, E., additional, Garofalo, A., additional, and Blandino, G., additional

Published
2012
Full Text
View/download PDF

142. 261 Is prostate biopsy still necessary?

Author

Di, Silverio F., primary, Salciccia, S., additional, Busetto, G.M., additional, Panebianco, V., additional, Lisi, D., additional, Alfarone, A., additional, Parente, U., additional, Gentilucci, A., additional, Cattarino, S., additional, Innocenzi, M., additional, Giovannone, R., additional, Sciarra, A., additional, Passariello, R., additional, and Gentile, V., additional

Published
2012
Full Text
View/download PDF

144. 342 Use of multiparametric MR with neurovascular bundle evaluation to optimize the oncological and functional management of patients considered for nerve sparing radical prostatectomy

Author

Minisola, F., primary, Sciarra, A., additional, Panebianco, V., additional, Alfarone, A., additional, Cattarino, S., additional, Gentilucci, A., additional, Innocenzi, M., additional, Ravaziol, M., additional, Parente, U., additional, Salciccia, S., additional, and Gentile, V., additional

Published
2012
Full Text
View/download PDF

147. 707 VALUE OF MAGNETIC RESONANCE SPECTROSCOPY IMAGING (MRSI) AND DYNAMIC CONTRAST-ENHANCED IMAGING MR (DCEMR) FOR THE DETECTION OF PROSTATE ADENOCARCINOMA FOCI IN MEN WITH PRIOR NEGATIVE PROSTATE BIOPSY AND ELEVATED PROSTATE SPECIFIC ANTIGEN (PSA) LEVELS

Author

Sciarra, A., primary, Panebianco, V., additional, Salciccia, S., additional, Gentilucci, A., additional, Parente, U., additional, Alfarone, A., additional, Cattarino, S., additional, Lisi, D., additional, Passariello, R., additional, and Gentile, V., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results